Cargando…

A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol

OBJECTIVES: To evaluate the plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus (T2DM) and arteriosclerosis obliteran (ASO) when treated with Probucol plus Cilostazol in combination and individually. METHODS: In this open-label study, patients aged 40–75 years were randomized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Xiao-Wei, Guo, Xiao-Hui, Xiao, Xin-Hua, Guo, Li-Xin, Lv, Xiao-Feng, Li, Quan-Min, Gao, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Science Press 2012
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470020/ https://www.ncbi.nlm.nih.gov/pubmed/23097651 http://dx.doi.org/10.3724/SP.J.1263.2012.02143

Ejemplares similares

Comparison of efficacy between trimetazidine and cilostazol in the treatment of arteriosclerosis obliterans in lower extremity
por: Hu, Min, et al.
Publicado: (2019)

Clinical Efficacy of Interventional Therapy on Lower Extremity Arteriosclerosis Obliterans and Prognostic Factors
por: Xiao, Deshuang, et al.
Publicado: (2022)

Application of E-coach chronic disease management model in rehabilitation management of patients with arteriosclerosis obliterans
por: Yuan, You-Yuan, et al.
Publicado: (2023)

Effects of aspirin combined with cilostazol on thromboangiitis obliterans in diabetic patients
por: Yong, Jun, et al.
Publicado: (2018)

Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits
por: Wang, Yanli, et al.
Publicado: (2015)

Loss of GRB2 associated binding protein 1 in arteriosclerosis obliterans promotes host autophagy
por: Ye, Meng, et al.
Publicado: (2021)

Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans
por: Yong, Jun, et al.
Publicado: (2019)

Relationship between Angiotensin II, Vascular Endothelial Growth Factor, and Arteriosclerosis Obliterans
por: Liu, Yulian, et al.
Publicado: (2023)

Cilostazol and Probucol for Cognitive Decline after Stroke: A Cognitive Outcome Substudy of the PICASSO Trial
por: Lim, Jae-Sung, et al.
Publicado: (2021)

Microarray Expression Profile and Bioinformatic Analysis of Circular RNA in Human Arteriosclerosis Obliterans
por: Zhou, Yu, et al.
Publicado: (2023)

Mechanisms underlying probucol-induced hERG-channel deficiency
por: Shi, Yuan-Qi, et al.
Publicado: (2015)

Probucol plus cilostazol attenuate hypercholesterolemia-induced exacerbation in ischemic brain injury via anti-inflammatory effects
por: KIM, JI HYUN, et al.
Publicado: (2014)

Expression and clinical significance of HSP27 and its phosphorylation in lower extremity arteriosclerosis obliterans
por: Bai, Junqing, et al.
Publicado: (2020)

HSPB1 Regulates Autophagy and Apoptosis in Vascular Smooth Muscle Cells in Arteriosclerosis Obliterans
por: Chen, Keqin, et al.
Publicado: (2022)

Retracted: Clinical Efficacy of Interventional Therapy on Lower Extremity Arteriosclerosis Obliterans and Prognostic Factors
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Add-On Effect of Probucol in Atherosclerotic, Cholesterol-Fed Rabbits Treated with Atorvastatin
por: Keyamura, Yuka, et al.
Publicado: (2014)

Virtual Reality-Assisted Percutaneous Transluminal Angioplasty for Interventional Treatment of Lower-Extremity Arteriosclerosis Obliterans
por: Zhou, Ruhang, et al.
Publicado: (2021)

Cilostazol on the expression of ICAM-1, VCAM-1 and inflammatory factors in plasma in patients with thromboangiitis obliterans
por: Song, Fuchen, et al.
Publicado: (2018)

Combined Therapeutic Effect of Probucol and Cilostazol on Endothelial Function in Patients with Silent Cerebral Lacunar Infarcts and Hypercholesterolemia: A Preliminary Study
por: Takase, Bonpei, et al.
Publicado: (2013)

Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study
por: Kang, Hyun-Jae, et al.
Publicado: (2021)

Neutrophil gelatinase-associated lipocalin as an early predictor of contrast-induced nephropathy following endovascular therapy for arteriosclerosis obliterans
por: Liu, Zhenjie, et al.
Publicado: (2020)

Predictive Value of Contrast-Enhanced Ultrasound in Chemical Lumbar Sympathectomy for End-Stage Arteriosclerosis Obliterans of the Lower Extremities
por: Wu, Yue, et al.
Publicado: (2022)

MicroRNA-30a-3p: a potential noncoding RNA target for the treatment of arteriosclerosis obliterans
por: Zhang, Mao, et al.
Publicado: (2023)

Effects of probucol on atherosclerotic plaque and soluble thrombomodulin in patients with coronary heart disease
por: Liu, Donghai, et al.
Publicado: (2018)

Ameliorative effects of the traditional Chinese medicine formula Qing-Mai-Yin on arteriosclerosis obliterans in a rabbit model
por: Zhang, Lei, et al.
Publicado: (2020)

Novel Insight Into Long-Term Risk of Major Adverse Cardiovascular and Cerebrovascular Events Following Lower Extremity Arteriosclerosis Obliterans
por: Sun, Ji, et al.
Publicado: (2022)

Retracted: Virtual Reality-Assisted Percutaneous Transluminal Angioplasty for Interventional Treatment of Lower-Extremity Arteriosclerosis Obliterans
por: Healthcare Engineering, Journal of
Publicado: (2023)

Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis
por: Chen, Yingqing, et al.
Publicado: (2016)

Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE)
por: Yamashita, Shizuya, et al.
Publicado: (2021)

The clinical significance of serum HMGB1 in patients with lower extremity arteriosclerosis obliterans after interventional vascular restenosis
por: Yang, Bo, et al.
Publicado: (2023)

Overexpression of ABCG1 protein attenuates arteriosclerosis and endothelial dysfunction in atherosclerotic rabbits
por: Münch, Götz, et al.
Publicado: (2012)

Integrated Analysis of Two Probucol Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT
por: Arai, Hidenori, et al.
Publicado: (2022)

Effect of Recombinant Netrin-1 Protein Combined with Peripheral Blood Mesenchymal Stem Cells on Angiogenesis in Rats with Arteriosclerosis Obliterans
por: Zeng, Jie, et al.
Publicado: (2022)

MicroRNA-31 promotes arterial smooth muscle cell proliferation and migration by targeting mitofusin-2 in arteriosclerosis obliterans of the lower extremitie
por: Huang, Shuichuan, et al.
Publicado: (2018)

Effects of Drug-Coated Balloon Therapy on CT Imaging Results and Levels of Vascular Inflammatory Cytokines in Patients with Arteriosclerosis Obliterans Lesions
por: Yang, Yanlin
Publicado: (2022)

Arteriosclerosis
Publicado: (1925)

Arteriosclerosis
Publicado: (1913)

Probucol-induced hERG Channel Reduction can be Rescued by Matrine and Oxymatrine in vitro
por: Shi, Yuan-Qi, et al.
Publicado: (2019)

Protective effect of rivaroxaban on arteriosclerosis obliterans in rats through modulation of the toll-like receptor 4/NF-κB signaling pathway
por: Lou, Xinjiang, et al.
Publicado: (2019)

Effects of Valsartan on Restenosis in Patients with Arteriosclerosis Obliterans of the Lower Extremities Undergoing Interventional Therapy: A Prospective, Randomized, Single-Blind Trial
por: Yao, Wei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rgj72tslkt5hmmkt1d0umagvg7